TNDM earnings call summary

Prepared Highlights

• Q2 2025 worldwide sales of $241M set a record for highest second-quarter sales in both U.S. and OUS markets (CFO).
• U.S. sales in Q2 were $170M, up 9% YoY; international sales were $70M, also a record second quarter (CFO).
• Year-to-date worldwide sales reached $475M, growth of 15% (CFO).
• Renewals were just over half of U.S. pump shipments, with double-digit growth in renewals YoY (CEO).
• People converting from MDI made up about 2/3 of new pump starts in Q2 (CEO).
• Q2 gross margin was 52%, up YoY and QoQ; pricing was the primary driver, partially offset by product mix and non-manufacturing costs (CFO).
• Operating expenses grew 10% YoY, driven by SG&A investments; R&D expenses were essentially flat YoY (CFO).
• Ended Q2 with $315M in total cash and investments; used $41M to settle 2025 convertible notes and paid $8M as first of five annual installments on a $36M settlement agreement (CFO).
• Official guidance: Full-year 2025 worldwide sales expected to reach $1B; U.S. sales ~$700M, OUS ~$300M; gross margin guidance of 53%–54%; adjusted EBITDA guidance recast from positive 3% to negative 5% due to $75M IP R&D charge in Q1 (CFO).
• Anticipate returning to positive free cash flow in H2 2025 (CFO).
• Pharmacy channel currently covers ~30% of U.S. lives; beginning Q4 2025, plan to start selling t:slim supplies through pharmacy channel (CFO).
• Steadiset 510(k) submitted in Q2 for extended wear time; extended wear technology now incorporated in Mobi tubeless design (CEO).

Mgmt Quotes

• "We achieved record second quarter sales, both in the U.S. and internationally." (CEO)
• "Renewals were just over half of our pump shipments and is a trend we anticipate will continue through the end of the year, which demonstrates our strong retention." (CEO)
• "Our entry into the pharmacy channel was predicated on 2 objectives: to lower out-of-pocket costs for our patients and to drive sales and margins more in line with industry comps." (CFO)
• "The Mobi cost per pump has already improved meaningfully year-over-year, and the platform margins are expected to continue improving over the course of the year as pump and cartridge volumes grow." (CFO)
• "We remain on track to reach the quarterly milestone of 60% gross margin as we exit 2026." (CFO)

Prepared Metrics

Q&A Batch (1-5 of 18)

Q1 — Matthew Stephan Miksic

• Topic: CMS提案对业务的影响
• Key points:
  • 管理层认为该提案不会对业务产生重大影响，反而可能推动更多人使用胰岛素泵治疗。
  • 传统Medicare占公司销售额不到10%。
  • 向“按使用付费”模式过渡是商业策略中已考虑过的方向（如药房渠道），对Medicare的转型视为积极因素。
• Mgmt stance: bullish – 认为影响不大且可能带来正面推动，公司将参与评议期并关注最终裁决。

Q2 — Matthew Charles Taylor

• Topic: 药房渠道进展与定价
• Key points:
  • 药房渠道目前仅涉及Mobi产品，占美国整体销售额比例很小，但定价相对于DME渠道有溢价。
  • 目前已覆盖约30%的有保险人群，预计未来几周将签署更多合同以扩大覆盖。
  • t:slim耗材进入药房渠道的益处将从第四季度开始显现，是2026年业务增长的关键杠杆之一。
  • 管理层目前未给出2026年的具体数字指引。
• Mgmt stance: bullish – 将此渠道视为收入增长和利润改善的机会，并积极推动覆盖扩展。

Q3 — Christopher Thomas Pasquale

• Topic: 国际业务（OUS）指引上调原因
• Key points:
  • 国际业务上半年表现强劲，分销商去库存（destocking）的逆风低于预期，原估计为1500万-2000万美元，现修正为约1000万美元。
  • 在部分市场已开始看到续约（renewal）机会的早期迹象，这将成为美国以外市场新的增长动力。
• Mgmt stance: bullish – 由于实际去库存影响小于预期以及续约机会显现，管理层上调了国际市场的全年指引。

Q4 — William John Plovanic

• Topic: 美国市场新患者及续约情况
• Key points:
  • 美国市场出货量中，续约（renewals）实现两位数增长，占本季度出货量的一半以上。
  • 新患者增长中，MDI（每日多次注射）转换增长快于竞争性转换（competitive conversions）。
  • 竞争性转换面临一定逆风，与一家大型竞争对手的业务演变有关，且该机会今年总量较往年更低。
• Mgmt stance: neutral – 续约业务稳健，但竞争转换存在持续逆风，公司专注于驱动MDI机会。

Q5 — Shagun Singh Chadha

• Topic: 美国市场指引下调及下半年趋势
• Key points:
  • 美国指引下调至约7亿美元，原因是多项业务转型（如药房渠道、商业系统现代化、销售团队扩张、国际直营等）仍在实施中，部分收益延迟。
  • 本季度有一个新的市场进入者，其销售组织规模超出预期，预计将在下半年产生噪音并可能引发观望。
  • 第三季度全球收入预期约为2.35亿美元，环比略有下降（因Q2有部分美国库存增加和外汇收益），第四季度预计季节性走强。
• Mgmt stance: cautious – 管理层对内部分转型进展表示肯定，但考虑到外部竞争压力和内部工作仍在进行，对下半年采取现实且谨慎的展望。

Q&A Batch (6-10 of 18)

Q6 — Lawrence H. Biegelsen

• Topic: 持续双位数增长目标及2026年更新机会
• Key points:
  • "sustained double-digit growth" 是长期目标，并非仅指2026年。
  • 经常性业务（续约+耗材）占美国销售的75%。
  • 2026年新续约机会数量与2025年持平，但因瀑布效应（保修到期后18个月内捕获约70%客户），仍有可观增长空间。
• Mgmt stance: 中性偏积极，解释依赖续约的尾部效应驱动2026年增长。

Q7 — Joshua Thomas Jennings

• Topic: 毛利率指引维持53%-54%的原因
• Key points:
  • 毛利率改善来源：Mobi平台泵单位成本随产量增加而下降；Mobi cartridge成本改善预计2026年显现，但2025年底开始部分受益。
  • 药房渠道扩张（t:slim耗材进入）进一步增厚利润率。
  • 地理组合变化（美国vs国际）使毛利率指引维持在53%-54%。
• Mgmt stance: 中性，明确指出地理mix是抵消因素，整体利润改善来自成本和渠道。

Q8 — Danielle Joy Antalffy

• Topic: 新患者启动、泵出货量及市场竞争态势
• Key points:
  • 公司是耐用泵启动的领导者，预计保持该地位。
  • 市场仍在增长且渗透不足，公司有空间与竞争对手共同增长。
  • 通过产品组合和药房渠道扩张（降低患者自付费用）吸引更多患者。
• Mgmt stance: 自信，认为能维持领导地位，未直接评论竞争压力。

Q9 — David Harrison Roman

• Topic: 多泵平台策略的可持续性与资源效率
• Key points:
  • 组合策略（触摸屏300单位储药器、Mobi有管/无管、未来无管泵）覆盖市场细分需求。
  • 组织内部推动设计、App和传感器集成的效率提升。
  • R&D支出连续季度持平（flat over the last quarter），同时维持创新管线。
• Mgmt stance: 坚定支持组合策略，认为当前资源足以执行，且通过效率优化控制成本。

Q10 — Richard Samuel Newitter

• Topic: 2型糖尿病适应症的有限规模启动及后续扩张
• Key points:
  • 2型适应症使可寻址市场规模翻倍。
  • 试点季度中，试点区域2型采用率表现更好。
  • 当前正在将2型推广至大量新区域，并计划年内持续扩张。
• Mgmt stance: 积极，认为试点成功，基于经验谨慎加速扩张。

Q&A Batch (11-15 of 18)

Q11 — Jeffrey D. Johnson

• Topic: International pump start trends and guidance consistency
• Key points:
  • Q1 recognized ~$5 million of orders (pump and supply) originally anticipated in Q2, causing a timing shift between quarters.
  • Placements on patients grew year-over-year, despite external shipment numbers not reflecting demand.
  • Began destocking in one key market where TNDM plans to go direct next year; shipments were lower but placements still showed growth.
• Mgmt stance: Neutral — acknowledges timing and destocking distortions, but confirms underlying patient placement growth.

Q12 — Michael Holden Kratky

• Topic: Confidence in achieving 60% gross margin target exiting 2026
• Key points:
  • 60% refers to quarterly rate as exiting 2026, not full-year average; gross margin scales from Q1 to Q4 due to U.S. pump shipment seasonality.
  • Current exit rate this year is mid- to high 50s; reaching 60% in a year is "not a stretch."
  • Incremental opportunity from pharmacy expansion with t:slim supplies: hundreds of thousands of existing t:slim customers can transition to pharmacy channel for supplies without new pump purchases, increasing profits.
  • Mobi pump is now showing results as a proof point.
• Mgmt stance: Bullish — cites seasonal scaling, pharmacy transition opportunity, and Mobi's realized contribution.

Q13 — Anthony Charles Petrone

• Topic: Libre 3 + t:slim opportunity and white space
• Key points:
  • Abbott has 300,000–400,000 U.S. Libre 3 users not on pump therapy.
  • Early access underway; full commercial availability planned for fall.
  • OUS markets: a competitor with FreeStyle Libre integration has ~50,000 users in a relatively short period.
  • U.S. market research indicates interest in pump therapy among those not currently using it.
• Mgmt stance: Bullish — sees a "wide-open opportunity" with a large addressable base and existing OUS proof point.

Q14 — Joanne Karen Wuensch

• Topic: International expansion outlook into 2026
• Key points:
  • First half of 2025: investments in OUS markets (systems, hiring talent, market research) to prepare for direct operations.
  • Transitioning to direct operations expected to improve revenue and margins by removing distributor pricing pressure.
  • Direct model provides product intimacy that distributors may lack.
• Mgmt stance: Bullish — expects revenue and margin benefit from direct transitions, with structural advantages.

Q15 — Travis Lee Steed

• Topic: Lowered U.S. guidance — commercial evolution vs. competitive headwinds
• Key points:
  • Commercial transformation includes sales force expansion, system/tool/process upgrades for sales team and HCP interactions.
  • Key metrics: productivity improved quarter-over-quarter in H1, but new systems and teams not fully implemented.
  • New competitor with large sales force entered market; any new product causes pausing.
  • Both factors (incomplete implementation and new competition) contributed to the lower guide; difficult to separate.
• Mgmt stance: Cautious — being realistic about H2 due to incomplete implementation and competitive pause effect.

Q&A Batch (16-18 of 18)

Q16 — William John Plovanic

• Topic: Pharmacy channel inventory contribution in Q2 and Q3 outlook
• Key points:
  • Pharmacy contributed a “few million dollars” of benefit in Q2 (not specifically quantified).
  • U.S. Q2 revenue was “basically in line” with expectations, boosted by this stocking.
  • Q3 U.S. revenue expected to see a “similar type of step down” from Q2 due to seasonality and stocking dynamics.
• Mgmt stance: Neutral – acknowledges a temporary benefit but frames it as a normal seasonal pattern; sees expanded distributor networks as important for future pharmacy opportunity.

Q17 — Jayson Tyler Bedford

• Topic: U.S. pump guidance mix between new users and renewals in 2025
• Key points:
  • Renewals now expected to be “a little more than half” of total pump shipments for the year.
  • Original assumption was new pump starts growing mid-single digits year-over-year; now expected to be “flat to slightly down.”
  • The primary change in the guidance update is driven by lower expectations for new pump starts.
• Mgmt stance: Cautious – downgraded new user growth outlook, leading to a shift in mix toward renewals.

Q18 — Anthony Charles Petrone

• Topic: Type 2 retention rates and product pipeline updates (Steadiset, Tubeless Mobi)
• Key points:
  • Type 2 shipments have been “mid or high single digits” as a percent of overall shipments historically.
  • Management does not see a difference in retention rates between type 1 and type 2 customers.
  • Steadiset (extended wear infusion) submitted for approval; plans to launch in U.S. markets in 2026.
  • Tubeless Mobi (tubeless pump with independent cartridge/site change) in DMB testing and manufacturing build-out; also plans to launch in U.S. markets in 2026.
• Mgmt stance: Bullish – excited about type 2 reimbursement progress and two 2026 product launches (Steadiset and Tubeless Mobi) to improve competitiveness.